A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Gefitinib (Primary) ; Metformin (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CGMT
- 14 Aug 2019 Primary endpoint (PFS) has not been met, according to the results published in the Clinical Cancer Research.
- 14 Aug 2019 Results published in the Clinical Cancer Research
- 04 Jun 2019 Results assessing metformin's first-line use alongside gefitinib in patients without diabetes presented at the 55th Annual Meeting of the American Society of Clinical Oncology